Key result
Rosiglitazone treatment in a db/db diabetic mouse model restored the normal expression of 251 mRNAs and 10 lncRNAs, potentially acting through the TNFα-NFκb pathway.
Why the study?
The regulatory effects of long noncoding RNAs on the pathogenesis of diabetic nephropathy and the efficacy of rosiglitazone treatment remained undefined.
Does rosiglitazone treatment alter the expression of lncRNAs and mRNAs in a db/db diabetic mouse model of diabetic nephropathy?
Does rosiglitazone treatment alter the expression of lncRNAs and mRNAs in a db/db diabetic mouse model of diabetic nephropathy?
Rosiglitazone treatment in a diabetic nephropathy mouse model restores the expression of specific mRNAs and lncRNAs, highlighting lncRNA-AI838599 and the TNFα-NFκb pathway as potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
Rosiglitazone restores lncRNA/mRNA expression in diabetic mouse nephropathy; hypothesis-generating for TNFα-NFκB targeting before human translation.
Diabetic nephropathy (DN) is characterized by metabolic disorder and inflammation. However, the regulatory effects that long noncoding RNAs (lncRNAs) have on the pathogenesis of DN and on the efficacy of rosiglitazone treatment have yet to be clearly defined. Herein, we performed unbiased RNA sequencing to characterize the transcriptomic profiles in db/db diabetic mouse model with or without rosiglitazone treatment that served to improve the phenotypes of DN. Moreover, RNA‐seq profiling revealed that the development of DN caused an upregulation in the expression of 1176 mRNAs and a downregulation in the expression of 1010 mRNAs compared to controls, with the expression of 251 mRNAs being returned to normal following treatment with rosiglitazone. Further, 88 upregulated and 68 downregulated lncRNAs were identified in db/db mice compared to controls, 10 of which had their normal expression restored following treatment with rosiglitazone. Bioinformatic analysis revealed that the primary pathways involved in the pathogenesis of DN, and subsequently in the therapeutic effects of PPAR γ , are related to inflammatory and metabolic processes. From bioinformatics analysis, lncRNA‐AI838599 emerged as a novel molecular mechanism for rosiglitazone treatment in DN through TNF α ‐NF κ b pathway. These findings may indicate a new molecular regulatory approach for the development of DN therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied Diabetic nephropathy. Rosiglitazone vs. Control (db/db mice without treatment) was evaluated on Transcriptomic profiles (mRNAs and lncRNAs expression). Rosiglitazone treatment in a db/db diabetic mouse model restored the normal expression of 251 mRNAs and 10 lncRNAs, potentially acting through the TNFα-NFκb pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: